Try Alerts Free   |   Login
Health Care › Pharmaceutical Preparations

DCPH Price Correlated With Financials For Deciphera Pharmaceuticals

Free historical financial statements for Deciphera Pharmaceuticals Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 19 quarters since 2018. Compare with DCPH stock chart to see long term trends.

DCPH Stock Compared to Quarterly

DCPH Income Statement

Revenue, Net:35974000
Revenue Per Share:0.46
Cost of Goods & Services Sold:3344000
Selling, General & Admin Expense:30026000
Research & Development Expense:47485000
Total Operating Expenses:80855000
Operating Income:-44881000
Net Income:-43043000
Earnings Per Share, Basic:-0.55
Shares Outstanding, Basic Avg:78206647

DCPH Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:742000
Change in Accounts Receiveable:-2383000
Net Cash from Operations:-20828000
Net Cash from Operations Per Share:-0.2663
Net Cash from Financing Activities:209000
Property, Plant & Equipment Purchases:573000
Net Cash from Investing Activities:-6071000
Net Change in Cash & Equivalents:-26690000

DCPH Balance Sheet

Cash and Cash Equivalents:82538000
Accounts Receivable, Net:23278000
Inventories:19129000
Total Current Assets:420879000
Property, Plant & Equipment, Net:7152000
Total Assets:475952000
Accounts Payable:12800000
Total Short-Term Liabilities:75468000
Total Liabilities:102176000

Insider Trading

 
Change
Value
Transaction
SEC Form 4
Brightstar Associates LLC   10% Owner
1,666,666 sh at $18
$29,999,988
Buy

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock Inc.
5,211,863 sh
-316,879 sh
-6%
$96,419
$23,715
Vanguard Group Inc
4,794,993 sh
402,047 sh
9%
$88,708
$30,940
Armistice Capital, LLC
4,768,000 sh
-632,000 sh
-12%
$88,208
$17,198
Goldman Sachs Group Inc
3,766,853 sh
103,034 sh
3%
$69,687
$21,508
State Street Corp
3,219,331 sh
-711,586 sh
-18%
$59,558
$7,866
Redmile Group, LLC
2,973,029 sh
1,542,112 sh
108%
$55,001
$36,184
Deerfield Management Company, L.P. (Series C)
2,491,490 sh
-3,759,474 sh
-60%
$46,093
-$36,107
Assenagon Asset Management S.A.
1,403,821 sh
699,071 sh
99%
$25,971
$16,704
Jacobs Levy Equity Management, Inc
1,311,556 sh
112,547 sh
9%
$24,264
$8,497
Polar Capital Holdings Plc
1,250,000 sh
-250,000 sh
-17%
$23,125
$3,400
New Leaf Venture Partners, L.L.C.
1,209,571 sh
 
$22,377
Avidity Partners Management Lp
1,191,800 sh
-8,200 sh
-1%
$22,048
$6,268
Dimensional Fund Advisors LP
1,047,533 sh
249,777 sh
31%
$19,379
$8,888
Millennium Management LLC
951,319 sh
318,383 sh
50%
$17,599
$9,276
Geode Capital Management, LLC
877,693 sh
52,087 sh
6%
$16,237
$5,381
Nuveen Asset Management, LLC
813,649 sh
669,851 sh
466%
$15,052
$9,875
D. E. Shaw & Co., Inc.
790,411 sh
623,526 sh
374%
$14,623
$12,428
Price T Rowe Associates Inc /Md/
716,757 sh
569,958 sh
388%
$13,261
$11,331
Morgan Stanley
601,703 sh
-305,493 sh
-34%
$11,131
-$798
Ikarian Capital, LLC
492,275 sh
492,275 sh
NEW
$9,107
$9,107
COMPANY PROFILE
Nature of the Business and Summary of Significant Accounting Policies Nature of the Business

Deciphera Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. Leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology, the Company designs kinase inhibitors to target the switch pocket region of the kinase with the goal of developing potentially transformative medicines. Through its patient-inspired approach, the Company seeks to develop a broad portfolio of innovative medicines to improve treatment outcomes. QINLOCK, the Company's switch-control kinase inhibitor, was engineered using its proprietary drug discovery platform and developed for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union (EU), Hong Kong, Switzerland, Taiwan, the United States (U.S.), and the United Kingdom (U.K.) for the treatment of fourth-line GIST. The Company wholly owns QINLOCK and all of its drug candidates with the exception of a development and commercialization out-license agreement for QINLOCK in Greater China. In addition to QINLOCK, the Company has identified and advanced multiple product candidates from its platform into clinical studies, including vimseltinib and DCC-3116.

The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, market acceptance and the successful commercialization of QINLOCK or any of the Company's current or future drug candidates for which it receives marketing approval, protection of proprietary technology, ability to complete late-stage clinical trials, ability to obtain and maintain regulatory approvals, compliance with government regulations, the impact of the novel coronavirus (COVID-19) pandemic on its operations, and the ability to secure additional capital to fund operations. QINLOCK and the Company's drug candidates currently under development will require significant additional research and development efforts, including extensive preclinical and/or clinical testing and regulatory approval. In addition to supporting its research and development efforts, the Company will be required to invest in the Company's commercial capabilities and infrastructure, to support its commercialization of QINLOCK, the Company's first approved drug, and any current or future drug candidate for which the Company obtains marketing approval. These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting capabilities. Even if the Company's drug development and commercialization efforts are successful, it is uncertain when, if ever, the Company will realize sufficient revenue to result in a profit from product sales of QINLOCK or any current or future drug candidates for which it receives marketing approval.

The full extent to which the COVID-19 pandemic, or the future outbreak of any other highly infectious or contagious diseases, may impact the Company's business, including its preclinical studies, clinical trial operations, or commercialization efforts will depend on continuously changing circumstances, which are highly uncertain and cannot be predicted at this time, such as the duration of such pandemic including future waves of infection, new strains of the virus that causes COVID-19, or the impact of effective vaccines, the actions taken to contain the pandemic or mitigate its impact, and the direct and indirect economic effects of the pandemic and containment measures, among others. The Company is continuing to monitor the long-term impact of COVID-19, if any, on its financial condition and results of operations. The ongoing fluidity of this situation precludes an

Data imported from Deciphera Pharmaceuticals Inc SEC filings. Check original filings before making any investment decision.